Effect of treatment on serum glial cell line-derived neurotrophic factor in depressed patients

Zhang, Xiaobin; Zhang, Zhijun; Xie, Chunming; Xi, Guangjun; Zhou, Honghui; Zhang, Yumei; Sha, Wei

doi:10.1016/j.pnpbp.2008.01.004

Cited by 81 publications

(67 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GDNF mRNA in peripheral cells was reduced in individuals during a major depressive episode compared to individuals in remission and to healthy controls (Otsuki et al 2008). Furthermore, an increase in serum GDNF concentrations was demonstrated after antidepressant pharmacological treatment (Zhang et al 2008) and electroconvulsive therapy (Zhang et al 2009). …”

Section: Peripheral Biomarkersmentioning

confidence: 99%

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

Fabbri

Hosák

Mößner

et al. 2016

The World Journal of Biological Psychiatry

View full text Add to dashboard Cite

Major depressive disorder (MDD) is a heritable disease with a heavy personal and socio-economic burden. Antidepressants of different classes are prescribed to treat MDD, but reliable and reproducible markers of efficacy are not available for clinical use. Further complicating treatment, the diagnosis of MDD is not guided by objective criteria, resulting in the risk of under-or overtreatment. A number of markers of MDD and antidepressant response have been investigated at the genetic, epigenetic, gene expression and protein levels. Polymorphisms in genes involved in anti-depressant metabolism (cytochrome P450 isoenzymes), antidepressant transport (ABCB1), glucocorticoid signalling (FKBP5) and serotonin neurotransmission (SLC6A4 and HTR2A) were among those included in the first pharmacogenetic assays that have been tested for clinical applicability. The results of these investigations were encouraging when examining patient-outcome improvement. Furthermore, a nine-serum biomarker panel (including BDNF, cortisol and soluble TNF-a receptor type II) showed good sensitivity and specificity in differentiating between MDD and healthy controls. These first diagnostic and response-predictive tests for MDD provided a source of optimism for future clinical applications. However, such findings should be considered very carefully because their benefit/cost ratio and clinical indications were not clearly demonstrated. Future tests may include combinations of different types of biomarkers and be specific for MDD subtypes or pathological dimensions.

show abstract

Section: Peripheral Biomarkersmentioning

confidence: 99%

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

Fabbri

Hosák

Mößner

et al. 2016

The World Journal of Biological Psychiatry

View full text Add to dashboard Cite

show abstract

“…Recently, both clinical and preclinical animal studies have demonstrated that multiple neurotrophic/growth factors, such as glial cell line-derived neu-rotrophic factor (GDNF), a member of the transforming growth factor ␤ superfamily, have been proposed to play an important role in the therapeutic effect of antidepressants (4,5). Glial cell line-derived neurotrophic factor has been shown to be decreased in the peripheral blood of patients with MDD (6), whereas blood levels of GDNF in MDD are increased after antidepressant treatment (7). These findings suggest that modulating GDNF production may be a key therapeutic effect of antidepressants.…”

Section: Major Depressive Disorder (Mdd)mentioning

confidence: 99%

Tricyclic Antidepressant Amitriptyline-induced Glial Cell Line-derived Neurotrophic Factor Production Involves Pertussis Toxin-sensitive Gαi/o Activation in Astroglial Cells

Hisaoka-Nakashima

Miyano

Matsumoto

et al. 2015

Journal of Biological Chemistry

View full text Add to dashboard Cite

Background: A significant non-neural, monoamine-independent mechanism underlies the antidepressant effect of amitriptyline. Results: Amitriptyline-evoked GDNF production is mediated by pertussis toxin (PTX)-sensitive G␣ i/o . Conclusion: PTX-sensitive G␣ i/o activation is critical for the cascade that underpins the biological effect of amitriptyline. Significance: Further elaboration of the intracellular mechanism of amitriptyline could lead to greater understanding of depression and novel antidepressant treatments.

show abstract

“…Reduced mRNA expression in leukocytes as well as reduced GDNF levels in serum have been reported in patients with major depression and bipolar disorder (Otsuki et al, 2008;Zhang et al, 2008Zhang et al, , 2010. However, increased GDNF circulating levels have also been reported in patients during manic and depressive episodes in bipolar patients (Barbosa et al, 2011;Rosa et al, 2006), and in patients with unipolar depression in brain tissue (Michel et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

Circulating Glial-derived neurotrophic factor is reduced in late-life depression

Diniz

Teixeira

Talib

et al. 2012

Journal of Psychiatric Research

View full text Add to dashboard Cite

Effect of treatment on serum glial cell line-derived neurotrophic factor in depressed patients

Cited by 81 publications

References 25 publications

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

Tricyclic Antidepressant Amitriptyline-induced Glial Cell Line-derived Neurotrophic Factor Production Involves Pertussis Toxin-sensitive Gαi/o Activation in Astroglial Cells

Circulating Glial-derived neurotrophic factor is reduced in late-life depression

Contact Info

Product

Resources

About